Your browser doesn't support javascript.
loading
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings.
Magliano, Dianna J; Chen, Lei; Islam, Rakibul M; Carstensen, Bendix; Gregg, Edward W; Pavkov, Meda E; Andes, Linda J; Balicer, Ran; Baviera, Marta; Boersma-van Dam, Elise; Booth, Gillian L; Chan, Juliana C N; Chua, Yi Xian; Fosse-Edorh, Sandrine; Fuentes, Sonsoles; Gulseth, Hanne L; Gurevicius, Romualdas; Ha, Kyoung Hwa; Hird, Thomas R; Jermendy, György; Khalangot, Mykola D; Kim, Dae Jung; Kiss, Zoltán; Kravchenko, Victor I; Leventer-Roberts, Maya; Lin, Chun-Yi; Luk, Andrea O Y; Mata-Cases, Manel; Mauricio, Didac; Nichols, Gregory A; Nielen, Mark M; Pang, Deanette; Paul, Sanjoy K; Pelletier, Catherine; Pildava, Santa; Porath, Avi; Read, Stephanie H; Roncaglioni, Maria Carla; Lopez-Doriga Ruiz, Paz; Shestakova, Marina; Vikulova, Olga; Wang, Kang-Ling; Wild, Sarah H; Yekutiel, Naama; Shaw, Jonathan E.
Affiliation
  • Magliano DJ; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Electronic address: dianna.magliano@baker.edu.au.
  • Chen L; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
  • Islam RM; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Carstensen B; Clinical Epidemiology, Steno Diabetes Center Copenhagen, Gentofte, Denmark.
  • Gregg EW; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Pavkov ME; Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Andes LJ; Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Balicer R; Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
  • Baviera M; Laboratory of Cardiovascular Prevention, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.
  • Boersma-van Dam E; Department of General Practice, Netherlands Institute for Health Services Research, Utrecht, Netherlands.
  • Booth GL; Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Chan JCN; Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
  • Chua YX; Epidemiology and Disease Control Division, Public Health Group, Ministry of Health, Singapore.
  • Fosse-Edorh S; Department of Non-Communicable Diseases and Trauma, Santé Publique France, Saint-Maurice, France.
  • Fuentes S; Department of Non-Communicable Diseases and Trauma, Santé Publique France, Saint-Maurice, France.
  • Gulseth HL; Department for Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
  • Gurevicius R; Center of Health Information, Institute of Hygiene, Vilnius, Lithuania; Faculty of Public Governance and Business, Mykolas Romeris University, Vilnius, Lithuania.
  • Ha KH; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
  • Hird TR; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Jermendy G; 3rd Medical Department, Bajcsy-Zsilinszky Hospital, Budapest, Hungary.
  • Khalangot MD; Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences, Kyiv, Ukraine; Endocrinology Department, Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.
  • Kim DJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
  • Kiss Z; 2nd Department of Medicine and Nephrological Center, Medical Faculty, University of Pécs, Pécs, Hungary.
  • Kravchenko VI; Komisarenko Institute of Endocrinology and Metabolism, National Academy of Medical Sciences, Kyiv, Ukraine.
  • Leventer-Roberts M; Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel; Department of Pediatrics and Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lin CY; General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Luk AOY; Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
  • Mata-Cases M; CIBER of Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III, Barcelona, Spain; DAP-Cat Group, Institut Català de la Salut, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Barcelona, Spain.
  • Mauricio D; CIBER of Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III, Barcelona, Spain; DAP-Cat Group, Institut Català de la Salut, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Barcelona, Spain; Department of Endocr
  • Nichols GA; Science Programs Department, Kaiser Permanente Center for Health Research, Portland, OR, USA.
  • Nielen MM; Department of General Practice, Netherlands Institute for Health Services Research, Utrecht, Netherlands.
  • Pang D; Epidemiology and Disease Control Division, Public Health Group, Ministry of Health, Singapore.
  • Paul SK; Melbourne EpiCentre, University of Melbourne, Melbourne, VIC, Australia.
  • Pelletier C; Centre for Surveillance and Applied Research, Public Health Agency of Canada, Ottawa, ON, Canada.
  • Pildava S; Research and Health Statistics Department, Centre for Disease Prevention and Control, Riga, Latvia.
  • Porath A; Research Institute, Maccabi Healthcare Services, Tel Aviv, Israel; Faculty of Health, Ben Gurion University, Beer-Sheva, Israel.
  • Read SH; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Roncaglioni MC; Laboratory of Cardiovascular Prevention, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.
  • Lopez-Doriga Ruiz P; Department for Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway.
  • Shestakova M; Diabetes Institute, Endocrinology Research Center, Moscow, Russia.
  • Vikulova O; Diabetes Institute, Endocrinology Research Center, Moscow, Russia.
  • Wang KL; General Clinical Research Center, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Wild SH; Usher Institute, University of Edinburgh, Edinburgh, UK.
  • Yekutiel N; Research Institute, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Shaw JE; Department of Diabetes and Population Health, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia; School of Life Sciences, Latrobe University, Bundoora, VIC, Australia.
Lancet Diabetes Endocrinol ; 9(4): 203-211, 2021 04.
Article in En | MEDLINE | ID: mdl-33636102
ABSTRACT

BACKGROUND:

Diabetes prevalence is increasing in most places in the world, but prevalence is affected by both risk of developing diabetes and survival of those with diabetes. Diabetes incidence is a better metric to understand the trends in population risk of diabetes. Using a multicountry analysis, we aimed to ascertain whether the incidence of clinically diagnosed diabetes has changed over time.

METHODS:

In this multicountry data analysis, we assembled aggregated data describing trends in diagnosed total or type 2 diabetes incidence from 24 population-based data sources in 21 countries or jurisdictions. Data were from administrative sources, health insurance records, registries, and a health survey. We modelled incidence rates with Poisson regression, using age and calendar time (1995-2018) as variables, describing the effects with restricted cubic splines with six knots for age and calendar time.

FINDINGS:

Our data included about 22 million diabetes diagnoses from 5 billion person-years of follow-up. Data were from 19 high-income and two middle-income countries or jurisdictions. 23 data sources had data from 2010 onwards, among which 19 had a downward or stable trend, with an annual estimated change in incidence ranging from -1·1% to -10·8%. Among the four data sources with an increasing trend from 2010 onwards, the annual estimated change ranged from 0·9% to 5·6%. The findings were robust to sensitivity analyses excluding data sources in which the data quality was lower and were consistent in analyses stratified by different diabetes definitions.

INTERPRETATION:

The incidence of diagnosed diabetes is stabilising or declining in many high-income countries. The reasons for the declines in the incidence of diagnosed diabetes warrant further investigation with appropriate data sources.

FUNDING:

US Centers for Disease Control and Prevention, Diabetes Australia Research Program, and Victoria State Government Operational Infrastructure Support Program.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Global Health / Internationality / Diabetes Mellitus, Type 2 / Data Aggregation / Income Type of study: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Lancet Diabetes Endocrinol Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Global Health / Internationality / Diabetes Mellitus, Type 2 / Data Aggregation / Income Type of study: Diagnostic_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Lancet Diabetes Endocrinol Year: 2021 Type: Article